26266 Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 

or before May 28, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by June 1, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Doreen Kezer 

at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/AboutAdvisory

Committees/ucm111462.htm for 

procedures on public conduct during 

advisory committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: May 5, 2010. 

Jill Hartzler Warner, 

Acting Associate Commissioner for Special 

Medical Programs. 

[FR Doc. 2010–11038 Filed 5–10–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel: Developing Novel 

Diagnostic Tests To Improve 

Surveillance for Antimicrobial 

Resistant Pathogens, Funding 

Opportunity Announcement CI10–002; 

Initial Review 

Correction: This notice was published 

in the Federal Register on April 23, 

2010, Volume 75, Number 78, page 

21339. The time and date, and place 

should read as follows: 

Time and Date: 

12 p.m.–3 p.m., May 18, 2010 

(Closed). 

Place: Teleconference. 

Contact Person for More Information: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, CDC, 1600 

Clifton Road, NE., Mailstop E60, 

Atlanta, GA 30333, Telephone: (404) 

498–2293. The Director, Management 

Analysis and Services Office, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: April 29, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–11189 Filed 5–10–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Safety and Occupational Health Study 

Section (SOHSS), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Times And Dates: 

8 a.m.–5 p.m., June 22, 2010. (Closed). 

8 a.m.–5 p.m., June 23, 2010. (Closed). 

Place: Omni Hotel, 500 California 

Street, San Francisco, California 94104, 

Telephone (415) 677–9494, Fax (415) 

273–3038. 

Status: These portions of the meeting 

will be closed to the public in 

accordance with provisions set forth in 

Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the 

Director, Management Analysis and 

Services Office, Centers for Disease 

Control and Prevention, pursuant to 

Section 10(d) Public Law 92–463. 

Purpose: The Safety and Occupational 

Health Study Section will review, 

discuss, and evaluate grant 

application(s) received in response to 

the Institute’s standard grants review 

and funding cycles pertaining to 

research issues in occupational safety 

and health, and allied areas. 

It is the intent of NIOSH to support 

broad-based research endeavors in 

keeping with the Institute’s program 

goals. This will lead to improved 

understanding and appreciation for the 

magnitude of the aggregate health 

burden associated with occupational 

injuries and illnesses, as well as to 

support more focused research projects, 

which will lead to improvements in the 

delivery of occupational safety and 

health services, and the prevention of 

work-related injury and illness. It is 

anticipated that research funded will 

promote these program goals. 

Matters to be Discussed: The meeting 

will convene to address matters related 

to the conduct of Study Section 

business and for the study section to 

consider safety and occupational healthrelated grant applications. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Price Connor, PhD., NIOSH Health 

Scientist, 1600 Clifton Road, NE., 

Mailstop E–20, Atlanta, Georgia 30333, 

Telephone (404) 498–2511, Fax (404) 

498–2571. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

the Agency for Toxic Substances and 

Disease Registry. 

Dated: April 29, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–11186 Filed 5–10–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute (NCI); 

National Institute of Allergy and 

Infectious Diseases (NIAID); National 

Institute of Arthritis and 

Musculoskeletal and Skin Diseases 

(NIAMS); and Office of Research on 

Women’s Health (ORWH), Office of the 

Director (OD), NIH 

AGENCY: National Institutes of Health 

(NIH). 

ACTION: Notice of Open Conference. 

Notice is hereby given that the NIH, 

an agency of the Department of Health 

and Human Services, in collaboration 

with the Lupus Foundation of America, 

Washington, DC, will hold a scientific 

conference. 

Title: ‘‘Systemic Lupus 

Erythematosus: From Mouse Models to 

Human Disease and Treatment.’’ 

Dates: September 2–3, 2010. 

Location: Lister Hill Auditorium, 

Building 38A, NIH, Bethesda, Maryland. 


emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 90 / Tuesday, May 11, 2010 / Notices 26267 

Purpose of the Meeting 

This meeting will bring basic research 

scientists working on models of 

autoimmune disease relevant to lupus 

together with clinicians treating lupus 

patients. There are numerous mouse 

models of lupus, but their relevance to 

the actual disease is still a subject for 

debate. Thus it is the purpose of this 

meeting to have participants discuss 

similarities, as well as differences, in 

mouse models with respect to the 

disease with the clinicians who actually 

treat patients. In addition, input is 

encouraged from clinical attendees 

regarding what markers in an animal 

model would be most important for 

monitoring the disease and assessing 

the effectiveness of treatment. It is 

hoped that one consequence of this 

meeting might be some consensus as to 

what is most important in any animal 

model and what animal models might 

be most useful in developing new 

markers and treatments for the disease. 

For more information, including the 

agenda and registration for this 

conference, please see http:// 

web.ncifcrf.gov/events/SystemicLupus/ 

default.asp. 

Contacts: 

Howard Young: Senior Investigator, 

NCI, NIH; 301–846–5700; 

younghow@mail.nih.gov. 

Silvia Bolland: Senior Investigator, 

NIAID, NIH; 301–443–3158; 

sb455w@nih.gov. 

Juan Rivera: Senior Investigator, 

NIAMS, NIH; 301–496–7592; 

riveraj@mail.nih.gov. 

Lisa Begg: Director of Research, 

ORWH, OD, NIH; 301–496–7853; 

beggl@od.nih.gov. 

Dated: May 5, 2010. 

Francis S. Collins, 

Director, National Institutes of Health. 

[FR Doc. 2010–11169 Filed 5–10–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group; Population Sciences 

Subcommittee. 

Date: June 17–18, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaylord National Hotel & 

Convention Center, 201 Waterford Street, 

National Harbor, MD 20745. 

Contact Person: Carla T. Walls, PhD, 

Scientific Review Officer, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd., Room 5b01, Bethesda, MD 

20892, (301) 435–6898, wallsc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: April 30, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–11073 Filed 5–10–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the meeting of the 

National Cancer Advisory Board. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4), and 552b(c)(6), Title 5 

U.S.C., as amended. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Cancer 

Advisory Board Ad hoc Subcommittee on 

Experimental Therapeutics. 

Open: June 21, 2010, 6:30 p.m. to 8 p.m. 

Agenda: Discussion on Experimental 

Therapeutics. 

Place: Embassy Suites, Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Dr. Joseph Tomaszewski, 

Executive Secretary, NCAB Ad hoc 

Subcommittee on Experimental 

Therapeutics, National Cancer Institute, 

National Institutes of Health, 31 Center Drive, 

Room 3A44, Bethesda, MD 20892–8345, 

(301) 496–8531. 

Name of Committee: National Cancer 

Advisory Board. 

Open: June 22, 2010, 8 a.m. to 4 p.m. 

Agenda: Program reports and 

presentations; business of the Board. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147. 

Name of Committee: National Cancer 

Advisory Board. 

Closed: June 22, 2010, 4 p.m. to 

adjournment. 

Agenda: Review of grant applications. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147. 

Name of Committee: National Cancer 

Advisory Board. 

Open: June 23, 2010, 8:30 a.m. to 12 p.m. 

Agenda: Program reports and 

presentations; business of the Board. 

Place: National Institutes of Health, 9000 

Rockville Pike, Building 31, C Wing, 6th 

Floor, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Dr. Paulette S. Gray, 

Executive Secretary, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Room 8001, 

Bethesda, MD 20892–8327, (301) 496–5147. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 


emcdonald on DSK2BSOYB1PROD with NOTICES